Dallas, TX (PRWEB) May 08, 2013
The National Plaintiff’s Law Firm of Baron and Budd is now handling lawsuits pertaining to the recall of Granuflo, the brand name of a dialysate (http://www.fda.gov/medicaldevices/safety/listofrecalls/ucm309990.htm
). Dialysate is used when a patient undergoes dialysis, a long-term medical treatment used to treat kidney conditions. Granuflo has been known to allegedly cause various health issues including heart attack and stroke. The Granuflo lawyers at Baron and Budd are currently working to aid patients and families that have allegedly endured significant health issues after using Granuflo (IN RE: FRESENIUS GRANUFLO/NATURALYTE. DIALYSATE PRODUCTS LIABILITY LITIGATION. MDL No. 2428, Dist. Of Mass).
“It is Baron and Budd’s mission to uncover the facts that manufacturers don’t want their customers to know,” said Russell Budd, co-founder and managing shareholder of Baron and Budd. "When important research uncovers dangerous side effects, that research should immediately be made public."
According a New York Times article dated June 15, 2012, Fresenius Medical Care is the manufacturer of Granuflo and the world’s largest producer of products and services for kidney dialysis. More than one-third of the over 400,000 Americans who undergo dialysis treatments go to Fresenius clinics each year. (http://www.nytimes.com/2012/06/15/health/fda-investigates-fresenius-for-failure-to-warn-of-risk.html?_r=0)
The New York Times also reported that the Federal Drug Administration (FDA) issued a Granuflo a recall on March 29, 2012 to change the drug’s prescribing instructions. The recall said that the use of Granuflo could potentially lead to significant heart problems in patients, such as low blood pressure and cardiac arrhythmia. However, Fresenius allegedly knew that the product could harm patients as early as November 2011, according to an internal company memo. (http://www.nytimes.com/2012/06/15/health/fda-investigates-fresenius-for-failure-to-warn-of-risk.html?_r=1&)
If you or someone you know has undergone dialysis with Granuflo treatments and experienced severe health complications, contact Baron and Budd’s Granuflo lawyers today at 1.866.855.4556 or email us at info (at) baronbudd (dot) com.
For more information about our Granuflo attorneys, visit Baron and Budd’s website here: http://baronandbudd.com/areas-of-practice/pharmaceuticals/granuflo-lawyer/.
For more than 35 years, Baron and Budd lawyers have been protecting the rights of people against negligent companies. The firm has an established track record of success when going up against large corporations, including pharmaceutical companies. Recently, our lawyers were involved in the litigation surrounding diabetes drug Avandia. Baron and Budd represented more than 7,000 patients allegedly harmed by Avandia use, and currently represents numerous states in lawsuits against manufacturer GlaxoSmithKline (In Re: Avandia Marketing, Sales Practices and Products Liability Litigation, MDL No. 1871, E.D. Pa.). In the 1990s, the firm was closely involved in the litigation surrounding then-popular diet drug Fen-Phen. The resulting settlement was valued at over $1.275 billion (In re Diet Drugs (Phentermine | Fenfluramine | Dexfenfluramine) Products Liability Litigation, Case No. 98- MDL No. 1203 (E.D. Pa.).
About Baron & Budd
The law firm of Baron & Budd, with offices in Dallas, Baton Rouge, Austin and Los Angeles, is a nationally recognized law firm with over 35 years of “Protecting What’s Right” for people, communities and businesses harmed by negligence. Baron & Budd’s size and resources enable the firm to take on large and complex cases. The firm represents individuals, governmental and business entities in areas as diverse as water contamination, Gulf oil spill, Qui Tam, California Proposition 65 violations, unsafe drugs and medical devices, Chinese drywall, deceptive advertising, consumer financial fraud, securities fraud and asbestos cancers such as mesothelioma.
Read the full story at http://www.prweb.com/releases/2013/5/prweb10700127.htm.
Copyright©2012 Vocus, Inc.
All rights reserved